| 1st May 2024 3:00 pm |
RNS |
Total Voting Rights |
| 1st May 2024 7:00 am |
RNS |
1st Quarter Results |
| 24th Apr 2024 7:00 am |
RNS |
US FDA accepts new indication filing for Jemperli |
| 19th Apr 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 17th Apr 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 17th Apr 2024 7:05 am |
RNS |
GSK announces additional EAGLE-1 results |
| 17th Apr 2024 7:00 am |
RNS |
Results from long-term data relating to Shingrix |
| 16th Apr 2024 2:11 pm |
RNS |
Amendment - Director/PDMR Shareholding |
| 16th Apr 2024 7:00 am |
RNS |
FDA accepts GSK meningitis vaccine candidate file |
| 15th Apr 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 4th Apr 2024 12:05 pm |
RNS |
Replacement - Total Voting Rights |
| 2nd Apr 2024 3:00 pm |
RNS |
Total Voting Rights |
| 26th Mar 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 25th Mar 2024 1:00 pm |
RNS |
Notice of AGM |
| 22nd Mar 2024 4:20 pm |
RNS |
Transfer of Treasury Shares |
| 22nd Mar 2024 3:36 pm |
RNS |
Director/PDMR Shareholding |
| 18th Mar 2024 9:30 am |
RNS |
New Phase III Jemperli data in endometrial cancer |
| 13th Mar 2024 3:48 pm |
RNS |
Director/PDMR Shareholding |
| 8th Mar 2024 5:12 pm |
RNS |
Board Committee Change |
| 7th Mar 2024 7:00 am |
RNS |
GSK announces positive Blenrep DREAMM-8 results |
| 6th Mar 2024 4:00 pm |
RNS |
ViiV LAI vs oral SOC data in adherence-challenged |
| 5th Mar 2024 5:24 pm |
RNS |
GSK Annual Report 2023 on Form 20-F |
| 5th Mar 2024 7:00 am |
RNS |
New ViiV LA formulation potential 4-month dosing |
| 1st Mar 2024 3:00 pm |
RNS |
Total Voting Rights |
| 1st Mar 2024 12:15 pm |
RNS |
GSK publishes Annual Report 2023 |
| 29th Feb 2024 7:05 am |
RNS |
Directorate Change |
| 29th Feb 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 26th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 26th Feb 2024 7:00 am |
RNS |
GSK announces positive EAGLE-1 headline results |
| 22nd Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 21st Feb 2024 7:00 am |
RNS |
ViiV LAI superior to orals in adherence-challenged |
| 20th Feb 2024 9:01 am |
RNS |
Julie Brown - External Appointment |
| 19th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 15th Feb 2024 3:32 pm |
RNS |
Director/PDMR Shareholding |
| 15th Feb 2024 7:00 am |
RNS |
GSK completes acquisition of Aiolos Bio |
| 13th Feb 2024 4:45 pm |
RNS |
Director/PDMR Shareholding - Replacement |
| 13th Feb 2024 3:40 pm |
RNS |
Director/PDMR Shareholding |
| 13th Feb 2024 3:35 pm |
RNS |
Director/PDMR Shareholding |
| 13th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 6th Feb 2024 7:10 am |
RNS |
FDA accepts Arexvy filing for adults 50-59 at risk |
